Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718835 · ClinicalTrials.gov registry record · Phase 2
Incentive-based Smoking Cessation for Methadone Patients
A Phase 2 study, sponsored by University of Vermont Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT00718835: Completed Phase 2 study, sponsored by University of Vermont Medical Center.
NCT00718835 is a Phase 2 study that has completed, run by University of Vermont Medical Center. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00718835, a Phase 2 study, has completed, sponsored by University of Vermont Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. The overarching goal of this project is to systematically develop a voucher-based contingency-management (CM) intervention for promoting initial and longer-term abstinence from cigarette smoking in patients receiving methadone or buprenorphine treatment for their opioid abuse.
Interventions
- BEHAVIORAL incentive-based contingency management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00718835 record still lists
NCT00718835 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 1 intervention - of which incentive-based contingency management is the first listed.
NCT00718835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00718835 about?
NCT00718835 is a clinical study titled "Incentive-based Smoking Cessation for Methadone Patients". The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. The overarching goal of this project is to systemati...
What is the current status of trial NCT00718835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2007-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00718835?
The interventions under investigation include: incentive-based contingency management (BEHAVIORAL).
Who is sponsoring clinical trial NCT00718835?
This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00718835's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia